We utilized these resources to investigate how germline HSD3B1 variant status impacts the somatic features, signaling pathways, and immune microenvironment in prostate cancers with the goal of further elucidating how HSD3B1 variant status may impact therapy response. This evidence concerns the gene HSD3B1 and prostate cancer.